natgillin/translations-raw huggingface dataset:
Like all medicines, Invirase/ritonavir can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Invirase/ ritonavir neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The most frequently (in more than ten in a hundred) reported side effects of saquinavir taken with ritonavir concern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness, vomiting, wind and abdominal pain being the most common.
Najpogosteje (pri več kot desetih od stotih) so poročali o neželenih učinkih sakvinavirja v kombinaciji z ritonavirjem v zvezi s prebavili, od teh so bili najpogostejši občutek slabosti, driska, utrujenost, bruhanje, vetrovi in bolečina v trebuhu.
Other, less frequently reported side effects (in more than one in a hundred but less than one in ten persons), which may occur are: rash, itching, eczema and dry skin, hair loss, dry mouth, headache, peripheral neuropathy (a disturbance of the nerves in the feet and hands that may take the form of numbness, pins and needles, shooting or burning pain), co-ordination problems, fainting, confusion, weakness, dizziness, depression, anxiety, mood swings, night sweats and hot flushes, inability to sleep, libido problems, taste alteration, warts, mouth ulcers, dehydration, abdominal discomfort, indigestion, fever, pain, constipation, decreased as well as increased appetite, inflammation of gastrointestinal tract, piles, discoloured faeces, visual disturbance, eye pain, raised blood pressure, infections of the respiratory tract, muscle spasms, joint pain, blood collection in the joint, painful urination and infections of the urinary tract, fever and shivering, shortness of breath and chest pain.
Drugi manj pogosti neželeni učinki (pri več kot eni od stotih, a manj kot eni od desetih oseb), ki se lahko pojavijo, so: izpuščaj, srbenje, ekcem in suha koža, izguba las, suha usta, glavobol, periferna nevropatija (motnja delovanja živcev v stopalih in dlaneh, ki se lahko kaže kot omrtvelost, mravljinčenje, prebadajoča ali pekoča bolečina), težave s koordinacijo, omedlevanje, zmedenost, oslabelost, omotica, depresija, tesnoba, nihanje razpoloženja, nočno potenje in navali vročine, nezmožnost spanja, težave z libidom, sprememba okusa, bradavice, razjede v ustih, dehidracija, neprijeten občutek v trebuhu, slaba prebava, povišana telesna temperatura, bolečina, zaprtje, zmanjšan in tudi povečan apetit, vnetje gastrointestinalnega trakta, hemoroidi, razbarvano blato, motnje vida, bolečina v očeh, povišan krvni pritisk, okužbe dihal, mišični krč, bolečina v sklepih, kopičenje krvi v sklepih, boleče uriniranje in okužbe urinarnega trakta, vročica in drhtenje, zasopljenost in bolečina v prsnem košu.
Furthermore, inflammation of the liver, fits, allergic reactions, sleepiness and abnormal renal function have been reported.
Poročali so o vnetju jeter, krčih, alergijskih reakcijah, zaspanosti in nenormalni ledvični funkciji.
Your doctor will test your blood regularly to detect possible abnormalities.
Vaš zdravnik vam bo redno pregledoval kri, da bi zaznal možne nenormalnosti.
Cases of diabetes mellitus or increased blood sugar levels have been reported in patients receiving this treatment or another protease inhibitor.
Pri bolnikih, ki so prejemali to zdravilo ali drug zaviralec proteaz, so poročali o primerih sladkorne bolezni ali povišanih koncentracijah krvnega sladkorja.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Kombinirano protiretrovirusno zdravljenje lahko povzroči spremenjeno obliko telesa zaradi sprememb razporeditve maščevja.
These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and other internal organs, breast enlargement and fatty lumps on the back of the neck (’buffalo hump’).
Te lahko vključujejo stanjšanje maščobne plasti pod kožo nog, rok ali obraza, povečano količino maščevja v trebuhu in drugih notranjih organih, povečanje dojk in maščobne grbe pod zatiljem (bivolja grba).
The cause and long-term health effects of these conditions are not known at this time.
Vzroki in dolgotrajni vplivi teh stanj na zdravje niso znani.
Combination antiretroviral therapy may also cause raised lactic acid and sugar in the blood, hyperlipaemia (increased fats in the blood) and resistance to insulin.
Kombinirano protiretrovirusno zdravljenje lahko povzroči tudi zvišane koncentracije mlečne kisline, povišan krvni sladkor, hiperlipemijo (povečano koncentracijo maščob v krvi) in odpornost na insulin.
There have been reports of muscle pain, tenderness or weakness, particularly with combination antiretroviral therapy including protease inhibitors and nucleoside analogues.
62 Poročali so o bolečinah v mišicah, občutljivosti na dotik v mišicah ali šibkosti mišic, posebno pri kombiniranem protiretrovirusnem zdravljenju, ki vključuje zaviralce proteaz in nukleozidne analoge.
60 If you experience any side effects that are not in this leaflet, please tell your doctor or pharmacist.
Če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Also, tell your doctor if you have any severe or unusual symptoms or if any side effect that you think you may have gets worse or persists.
Svojemu zdravniku povejte tudi, če imate hude ali nenavadne simptome ali če se kateri koli neželeni učinek, za katerega mislite, da ga imate, poslabša ali vztraja.
HOW TO STORE INVIRASE
SHRANJEVANJE ZDRAVILA INVIRASE
- The active substance is saquinavir.
- Zdravilna učinkovina je sakvinavir.
One capsule of Invirase contains 228.7 mg of saquinavir
Ena kapsula zdravila Invirase vsebuje 228, 7 mg
mesilate corresponding to 200 mg saquinavir.
sakvinavirjevega mesilata, kar ustreza 200 mg sakvinavirja.
- The other ingredients are lactose (anhydrous) 63.3 mg, microcrystalline cellulose, povidone,
- Pomožne snovi so brezvodna laktoza 63, 3 mg, mikrokristalna celuloza, povidon, natrijev
sodium starch glycollate, talc and magnesium stearate.
karboksimetilškrob, smukec in magnezijev stearat.
The capsule shell consists of gelatine, iron oxide black, red and yellow (E172), indigocarmine (E132), titanium dioxide (E171), and the printing ink contains titanium dioxide (E 171), shellac, soya lecithin, polydimethylsiloxane.
Ovojnica kapsule vsebuje želatino, črni, rumeni in rdeči železov oksid (E172), indigokarmin (E132), titanov dioksid (E171) in barvilo za tisk, ki vsebuje titanov dioksid (E171), šelak, sojin lecitin, polidimetilsiloksan.
Each half of the capsule shell is marked with the printing “ROCHE” and the code “0245”.
Vsaka polovica ovojnice kapsule je označena z napisom ” ROCHE ” in oznako ” 0245 ”.
Invirase is available in an amber glass bottle containing 270 capsules.
Zdravilo Invirase je na voljo v steklenički jantarne barve s 270 kapsulami.
Marketing Authorisation Holder Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.
Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW Velika Britanija
Manufacturer Roche Pharma AG, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.
Izdelovalec Roche Pharma AG Emil- Barell - Strasse 1 79639 Grenzach- Wyhlen Nemčija
62 This leaflet was last approved in
Navodilo je bilo odobreno
INFORMATION FOR THE USER
65 NAVODILO ZA UPORABO
Invirase 500 mg film -coated tablets Saquinavir
Invirase 500 mg filmsko obložene tablete sakvinavir
64 Treatment with Invirase/ritonavir has not been shown to reduce the risk of transmission of HIV to others through sexual contacts or contamination with blood.
66 Za zdravljenje z zdravilom Invirase/ ritonavirjem ni bilo dokazano, da bi zmanjševalo tveganje za prenos HIV na druge s spolnim stikom ali kontaminacijo s krvjo.
Therefore, before using this medicine, you should have told your doctor if you suffer from diabetes mellitus, diarrhoea, or if you have allergies (see section 4) or if you have an intolerance to some sugars (see section “Important information about an ingredient of Invirase”).
Obstajajo nekatera bolezenska stanja, ki jih morda imate ali ste jih imeli in zahtevajo posebno pozornost pred ali med jemanjem zdravila Invirase/ ritonavirja, zato pred uporabo tega zdravila povejte svojemu zdravniku, če imate sladkorno bolezen, drisko ali alergije (glejte poglavje 4) ali če imate intoleranco na nekatere sladkorje (glejte poglavje Pomebne informacije o nekaterih sestavinah zdravila Invirase).
Important information about an ingredient of Invirase Each film-coated tablet contains lactose (monohydrate) 38.5 mg.
Pomembne informacije o nekaterih sestavinah zdravila Invirase Vsaka filmsko obložena tableta vsebuje 38, 5 mg laktoze (monohidrat).
Invirase is provided as 500 mg film-coated tablet.
Zdravilo Invirase je na voljo v obliki 500 mg filmsko obloženih tablet.
For patients in whom the 500 mg film-coated tablet is not suitable, Invirase is also available in the form of 200 mg hard capsules.
Za bolnike, za katere 500 mg filmsko obložene tablete niso primerne, je na voljo tudi zdravilo Invirase v obliki 200 mg trdih kapsul.
The dosage of Invirase is two 500 mg film-coated tablets with one 100 mg capsule of Norvir (ritonavir) two times daily.
Odmerek zdravila Invirase sta dve 500 mg filmsko obloženi tableti z eno 100 mg kapsulo zdravila Norvir (ritonavir)
The film-coated tablets should be swallowed whole together with water.
Filmsko obložene tablete pogoltnite cele z vodo.
If you take more Invirase than you should If you have taken more than the prescribed dose of Invirase/ritonavir you must contact your doctor or pharmacist.
Če ste vzeli večji odmerek zdravila Invirase, kot bi smeli Če ste vzeli več zdravila Invirase/ ritonavirja, kot vam je predpisano, to povejte svojemu zdravniku ali farmacevtu.
66 If you forget to take Invirase Do not take a double dose to make up for a forgotten individual dose.
Če ste pozabili vzeti zdravilo Invirase Ne vzemite dvojnega odmerka, da bi nadomestili pozabljeni posamezni odmerek.
Other, less frequently reported side effects (in more than one in a hundred but less than one in ten persons), which may occur are: rash, itching, eczema and dry skin, hair loss, dry mouth, headache, peripheral neuropathy (a disturbance of the nerves in the feet and hands that may take the form of numbness, pins and needles, shooting or burning pain), co-ordination problems, fainting, confusion, weakness, dizziness, depression, anxiety, mood swings, night sweats and hot flushes, inability to sleep, libido problems, taste alteration, warts, mouth ulcers, dehydration, abdominal discomfort, indigestion, fever, pain, constipation, decreased as well as increased appetite, inflammation of gastrointestinal tract, piles, discoloured faeces, visual disturbance, eye pain, raised blood pressure, infections of the respiratory tract, muscle spasms, joint pain, blood collection in the joint, painful urination and infections of the urinary tract, fever and shivering, shortness of breath and chest pain.
Drugi manj pogosti neželeni učinki (pri več kot eni od stotih a manj kot eni od desetih oseb), ki se lahko pojavijo, so: izpuščaj, srbenje, ekcem in suha koža, izguba las, suha usta, glavobol, periferna nevropatija (motnja delovanja živcev v stopalih in dlaneh, ki se lahko kaže kot omrtvelost, mravljinčenje, prebadajoča ali pekoča bolečina),), težave s koordinacijo, omedlevanje, zmedenost, oslabelost, omotica, depresija, tesnoba, nihanje razpoloženja, nočno potenje in navali vročine, nezmožnost spanja, težave z libidom, sprememba okusa, bradavice, razjede v ustih, dehidracija, neprijeten občutek v trebuhu, slaba prebava, povišana telesna temperatura, bolečina, zaprtje, zmanjšan in tudi povečan apetit, vnetje gastrointestinalnega trakta, hemoroidi, razbarvano blato, motnje vida, bolečina v očeh, povišan krvni pritisk, okužbe dihal, mišični krč, bolečina v sklepih, kopičenje krvi v sklepih, boleče uriniranje in okužbe urinarnega trakta, vročica in drhtenje, zasopljenost in bolečina v prsnem košu.
These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and other internal organs, breast enlargement and fatty lumps on the back of the neck (’buffalo hump’).
Te lahko vključujejo stanjšanje maščobne plasti pod kožo nog, rok ali obraza, povečano količino maščevja v trebuhu in drugih notranjih organih, povečanje dojk in maščobne grbe
67 If you experience any side effects that are not in this leaflet, please tell your doctor or pharmacist.
Če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
One film -coated tablet of Invirase contains 500 mg of
500 mg sakvinavirja v obliki sakvinavirjevega mesilata.
saquinavir as saquinavir mesilate.
- Pomožne snovi so mikrokristalna celuloza, premreženi natrijev karmelozat, povidon, laktoza
(monohydrate) 38.5 mg, magnesium stearate, hypromellose, titanium dioxide (E 171), talc, glycerol triacetate, iron oxide yellow (E172) and iron oxide red (E172).
(monohidrat) 38, 5 mg, magnezijev stearat, hipromeloza, titanov dioksid (E171), smukec, gliceriltriacetat, rumeni železov oksid (E172) in rdeči železov oksid (E172).
Invirase 500 mg film-coated tablets are light orange to greyish or brownish orange tablets of oval shape with the marking "SQV 500" on the one side and "ROCHE" on the other side.
Invirase 500 mg filmsko obložene tablete so svetlo oranžne do sivkasto ali rjavkasto oranžne barve, ovalne oblike z oznako ''SQV 500'' na eni strani in ''ROCHE'' na drugi strani.
Marketing Authorisation Holder Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.
Imetnik dovoljenja za promet z zdravilom Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW Velika Britanija
Manufacturer Roche Pharma AG, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.
Izdelovalec Roche Pharma AG, Emil- Barell- Strasse 1, 79639 Grenzach- Wyhlen, Nemčija
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
70 Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)
Tél/ Tel: +32 (0) 2 525 82 11
Malta (See United Kingdom)
Tel: +44 (0) 1707 366000
United Kingdom Roche Products Ltd.
71 United Kingdom Latvija Roche Products Ltd.
69 This leaflet was last approved in
Navodilo je bilo odobreno
A doctor or a nurse applies the transdermal system to the patient ’ s skin on the chest or upper arm.
Zdravnik ali medicinska sestra namestita transdermalni sistem na bolnikovo kožo na prsih ali nadlahti.
IONSYS can be used up to six times in one hour, but for no more than 80 doses within a 24-hour period.
Zdravilo IONSYS se lahko uporabi največ šestkrat na uro, skupno število odmerkov pa ne sme biti več kot 80 odmerkov v 24- urnem obdobju.
The fourth study compared IONSYS to morphine given by injection into a vein, and looked at the number of patients who judged their pain relief as ‘ good’ or ‘ excellent’.
V tej študiji so beležili število bolnikov, ki so stopnjo olajšanja bolečine označili kot „ dobro “ ali „ odlično “.
(44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has IONSYS shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 85 45 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo IONSYS izkazalo med raziskavami?
Therefore, the Committee decided that IONSYS’ s benefits are greater than its risks for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
Odbor je zato odločil, da so koristi zdravila IONSYS pri nadzorovanju akutne zmerne do hude pooperativne bolečine pri njegovi uporabi samo v bolnišnicah večje od z njim povezanih tveganj.
The European Commission granted a marketing authorisation valid throughout the European Union for IONSYS to Janssen-Cilag International NV on 24 January 2006.
Evropska komisija je dovoljenje za promet z zdravilom IONSYS, veljavno po vsej Evropski uniji, odobrila družbi Janssen- Cilag International NV dne 24. januarja 2006.
This summary was last updated in 10-2007.
Ta povzetek je bil nazadnje posodobljen 10- 2007.
40 µg/ dose
40 µg/ odmerek
Iontophoretic transdermal system
Iontoforetski transdermalni sistem
Transdermal Use
Transdermalna uporaba
sachet Nylon/ Alu/ copolymer of polyethylene and polymethacrylic acid
vrečka najlon/ alu/ kopolimer polietilena in polimetakrilne kisline
1 sachet in carton
1 vrečka v škatlici
IONSYS 40 micrograms per dose iontophoretic transdermal system.
IONSYS 40 mikrogramov na odmerek iontoforetični transdermalni sistem.
Each IONSYS system contains 10.8 mg fentanyl hydrochloride equivalent to 9.7 mg of fentanyl and delivers 40 micrograms fentanyl per dose, to a maximum of 3.2 mg (80 doses).
Vsak sistem IONSYS vsebuje 10, 8 mg fentanilijevega klorida, kar ustreza 9, 7 mg fentanila in dovaja 40 mikrogramov fentanila na odmerek, do največ 3, 2 mg (80 odmerkov).
Iontophoretic transdermal system (ITS).
Iontoforetični transdermalni sistem (ITS).
IONSYS is composed of a compact electronic controller and two hydrogel reservoirs, one of which contains fentanyl hydrochloride in a gel formulation for needle free, on-demand delivery.
IONSYS sestoji iz kompaktnega elektronskega regulatorja in dveh rezervoarjev s hidrogelom, od katerih eden vsebuje fentanilijev klorid v gelu za brezigelno dajanje na zahtevo.
The upper part of the product is white and contains the identifier ‘ IONSYS™’.
Zgornji del sistema je bele barve in vsebuje identifikacijsko oznako ‘ IONSYS™ ’.
IONSYS is indicated for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
IONSYS je indiciran za zdravljenje akutne zmerne do hude pooperativne bolečine in je namenjen samo uporabi v bolnišnicah.
IONSYS should be restricted to hospital use only.
IONSYS se sme uporabljati samo v bolnišnicah.
Due to the well known potential of abuse of fentanyl physicians should evaluate patients for a history of drug abuse (see section 4.4).
Zaradi možne zlorabe fentanila, mora zdravnik oceniti bolnikovo zgodovino zlorabe drog (glejte poglavje 4. 4).
Special precautions for disposal should be followed (see section 6.6).
Upoštevati je treba posebne varnostne ukrepe za odstranjevanje (glejte poglavje 6. 6).
IONSYS should only be activated by the patient.
IONSYS sme aktivirati le bolnik.
Before any surgery, the healthcare professional should ensure that the patient has been properly informed on how to use IONSYS post-operatively.
Pred kirurškim posegom mora zdravstveni delavec zagotoviti, da je bolnik ustrezno poučen o postoperativni uporabi sistema IONSYS.
IONSYS delivers 40 micrograms per on-demand dose up to a maximum of 240 micrograms (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period.
IONSYS dovaja 40 mikrogramov zdravila na odmerek, dan na zahtevo, do največ 240 mikrogramov na uro (6 odmerkov, ki trajajo vsak po 10 minut), vendar ne več kot 80 odmerkov v 24- urnem obdobju.
Patients should be titrated to an acceptable level of analgesia prior to initiating use of IONSYS.
Pred začetkom uporabe zdravila IONSYS pri bolnikih titrirajte zdravljenje do sprejemljive ravni analgezije.
The system should only be activated by the patient in response to pain.
Sistem sme aktivirati le sam bolnik ob pojavu bolečine.
IONSYS will operate for 24 hours following completion of the first dose or for 80 doses, whichever comes first, and then becomes inoperative.
Sistem IONSYS bo deloval 24 ur po sprostitvi prvega odmerka ali dokler ne bo sprostil 80 odmerkov (kar nastopi prej), potem ne bo več deloval.
If the patient attempts to initiate a dose after 80 doses or 24 hours from the first dose, the system will not respond (i. e. no red light, no beep).
Če bo bo bolnik poskušal sprožiti odmerek po 80 odmerkih ali po 24 urah po prvem odmerku, se sistem ne bo odzval (t. j. rdeča lučka ne posveti, ni piska).
The maximum treatment duration is 72 hours (3 systems), although the majority of patients should only need one system.
Zdravljenje lahko traja največ 72 ur (3 sistemi), vendar naj bi pri večini bolnikov zadoščal že en sam sistem.
Patients should not wear more than one system at a time.
Bolnik ne sme nositi več kot enega sistema naenkrat.
Used systems should not be reapplied to a patient.
Že uporabljenih sistemov ne smete ponovno uporabiti pri bolniku.
Patients should not get the IONSYS system wet.
Bolniki sistema IONSYS ne smejo zmočiti.
Prolonged contact with water could affect system performance and cause the system to malfunction or fall off.
Daljši stik z vodo bi lahko vplival na delovanje sistema in povzročil napake v delovanju ali odpadanje sistema s kože.
IONSYS should be removed before the patient is discharged.
Sistem IONSYS je treba odstraniti, preden bolnika odpustite iz bolnišnice.
IONSYS is not recommended for use in children below age 18 years due to insufficient data on safety and efficacy.
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba sistema IONSYS pri otrocih pod 18 let ni priporočljiva.
Limited data on pharmacokinetics, safety and efficacy are available for the use of IONSYS in patients > 75 years.
O uporabi sistema IONSYS pri bolnikih > 75 let je na voljo omejena količina podatkov o farmakokinetiki, varnosti in učinkovitosti.
Elderly patients should be observed carefully for signs of fentanyl toxicity.
Starejše bolnike morate skrbno opazovati, da ugotovite znake toksičnosti fentanila.
Please refer to section 6.6.
Navodila za preizkus sistema IONSYS za farmacevte in druge zdravstvene delavce (preizkus opravite pred izdajozdravila): glejte poglavje 6. 6.
Method of Application
Namestitev sistema
The IONSYS system should not be used if the seal on the sachet is broken.
Sistema IONSYS ne smete uporabljati, če vrečka ni več vakuumsko zaprta.
LED = Light Emitting Diode
LED (Light Emitting Diode) = svetlobna dioda
IONSYS should be applied to intact, non-irritated and non-irradiated skin on the chest or upper outer arm.
IONSYS namestite na nepoškodovano, neobsevano kožo brez znakov draženja, na prsih ali na zunanjem delu nadlahti.
IONSYS should not be placed on abnormal skin sites, such as scars, burns, tattoos, etc.
Sistema IONSYS ne smete namestiti na nenormalna mesta na koži, na primer na brazgotine, opekline, tetovaže ipd.
Hair at the application site should be clipped (not shaved) before system application.
Pred namestitvijo sistema bolniku pristrizite dlake na tem mestu, ne smete pa jih obriti.
IONSYS should not be applied to a previously used skin site.
Sistema IONSYS ne smete namestiti na že prej uporabljeno mesto na koži.
The application site should be wiped with a standard alcohol swab, the skin allowed to dry completely before the IONSYS system is applied.
Mesto namestitve sistema je treba obrisati z navadnim alkoholnim tamponom, pustiti da se koža popolnoma posuši, preden nanjo namestite sistem IONSYS.
No soaps, oils, lotions, or any other agents that might irritate the skin or alter its absorption characteristics, should be used.
Ne smete uporabljati nobenih mil, olj, losjonov ali kakršnihkoli drugih sredstev, ki bi lahko povzročila draženje kože ali spremenila njene absorpcijske značilnosti.
The sachet containing IONSYS should be opened starting at the pre-cut notch, then by carefully tearing along the top of the sachet.
Vrečko s sistemom IONSYS je treba odpreti tako, da začnete na zarezanem delu in previdno odtrgate zgornji del.
The system should be removed from the sachet and used immediately.
Sistem je treba vzeti iz vrečke in ga takoj uporabiti.
The moisture absorber should be discarded after opening the sachet.
Po odprtju vrečke je treba zavreči sušilno sredstvo.
If no moisture absorber is present, or if the moisture absorber is not intact, do not use and return system to manufacturer.
Če v vrečki ni sušilnega sredstva ali je poškodovano, sistema ne uporabljajte in ga vrnite izdelovalcu.